JP2019519586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519586A5 JP2019519586A5 JP2018568791A JP2018568791A JP2019519586A5 JP 2019519586 A5 JP2019519586 A5 JP 2019519586A5 JP 2018568791 A JP2018568791 A JP 2018568791A JP 2018568791 A JP2018568791 A JP 2018568791A JP 2019519586 A5 JP2019519586 A5 JP 2019519586A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkyl
- hydroxyalkyl
- heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 49
- 125000000217 alkyl group Chemical group 0.000 claims 47
- 229910052760 oxygen Inorganic materials 0.000 claims 47
- 229910052799 carbon Inorganic materials 0.000 claims 46
- 125000000623 heterocyclic group Chemical group 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 28
- 229910052717 sulfur Inorganic materials 0.000 claims 27
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 23
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 23
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 22
- 125000004429 atom Chemical group 0.000 claims 22
- -1 C 1- C 6 alkoxyalkyl Chemical group 0.000 claims 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 19
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 18
- 229910052731 fluorine Inorganic materials 0.000 claims 18
- 125000005842 heteroatom Chemical group 0.000 claims 18
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 17
- 229910052794 bromium Inorganic materials 0.000 claims 16
- 229910052801 chlorine Inorganic materials 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052740 iodine Inorganic materials 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 206010019280 Heart failures Diseases 0.000 claims 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 4
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims 3
- 230000008484 agonism Effects 0.000 claims 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 claims 2
- PCJFEVUKVKQSSL-UHFFFAOYSA-N 2h-1,2,4-oxadiazol-5-one Chemical group O=C1N=CNO1 PCJFEVUKVKQSSL-UHFFFAOYSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims 1
- 125000006764 (C3-C9) halocycloalkyl group Chemical group 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 102000000072 beta-Arrestins Human genes 0.000 claims 1
- 108010080367 beta-Arrestins Proteins 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356215P | 2016-06-29 | 2016-06-29 | |
| US62/356,215 | 2016-06-29 | ||
| PCT/US2017/039646 WO2018005591A1 (en) | 2016-06-29 | 2017-06-28 | Biarylmethyl heterocycles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519586A JP2019519586A (ja) | 2019-07-11 |
| JP2019519586A5 true JP2019519586A5 (enExample) | 2020-12-17 |
| JP7231414B2 JP7231414B2 (ja) | 2023-03-01 |
Family
ID=59297443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568791A Active JP7231414B2 (ja) | 2016-06-29 | 2017-06-28 | ビアリールメチルヘテロサイクル |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11407733B2 (enExample) |
| EP (1) | EP3478672B1 (enExample) |
| JP (1) | JP7231414B2 (enExample) |
| KR (1) | KR102538999B1 (enExample) |
| CN (1) | CN109715615A (enExample) |
| AR (1) | AR108906A1 (enExample) |
| AU (1) | AU2017289974B2 (enExample) |
| BR (1) | BR112018077075A2 (enExample) |
| CA (1) | CA3029630A1 (enExample) |
| EA (1) | EA039493B1 (enExample) |
| ES (1) | ES2984389T3 (enExample) |
| IL (1) | IL263499B (enExample) |
| MX (1) | MX2018015247A (enExample) |
| SG (1) | SG11201810837QA (enExample) |
| TW (1) | TW201811759A (enExample) |
| WO (1) | WO2018005591A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10611757B2 (en) * | 2016-07-11 | 2020-04-07 | Wuhan Ll Science And Technology Development Co., Ltd. | Crystalline form of chemical compound, and preparation method, composition, and application thereof |
| WO2019071073A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN |
| CN109956870A (zh) * | 2017-12-14 | 2019-07-02 | 南京卡文迪许生物工程技术有限公司 | 一种罗沙司他的合成方法及其中间体化合物 |
| EP3556760A1 (en) * | 2018-04-19 | 2019-10-23 | F. Hoffmann-La Roche AG | Spiro compounds |
| CN112312904B (zh) | 2018-04-16 | 2025-01-07 | C4医药公司 | 螺环化合物 |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| AU2019356011B2 (en) | 2018-10-05 | 2025-02-06 | Forma Therapeutics, Inc. | Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors |
| HUE064377T2 (hu) | 2019-04-12 | 2024-03-28 | Riboscience Llc | Biciklusos heteroaril-származékok mint ektonukleotid pirofoszfatáz foszfodiészteráz 1 inhibitorok |
| MA55325A (fr) * | 2019-06-20 | 2022-04-27 | Chemocentryx Inc | Composés pour le traitement de maladies pd-l1 |
| CN110479182A (zh) * | 2019-09-10 | 2019-11-22 | 肯特催化材料股份有限公司 | 一种多氨基双子表面活性剂及其制备方法与应用 |
| GB201913603D0 (en) | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| MX2024001155A (es) * | 2021-07-30 | 2024-07-01 | Confo Therapeutics N V | Compuestos para el tratamiento del dolor, en particular el dolor neuropatico, y/u otras enfermedades o trastornos que se asocian con at2r y/o se?alizacion mediada por at2r. |
| TW202328116A (zh) * | 2021-08-26 | 2023-07-16 | 大陸商上海翰森生物醫藥科技有限公司 | 含芳環類生物拮抗劑、其製備方法及應用 |
| CN115321495B (zh) * | 2022-07-28 | 2023-07-21 | 东北石油大学 | 一种金属富氮化合物FeN8的合成方法 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444770A (en) | 1980-05-29 | 1984-04-24 | Bayer Aktiengesellschaft | New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use |
| CA1338238C (en) | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| CA2016710A1 (en) | 1989-05-15 | 1990-11-15 | Prasun K. Chakravarty | Substituted benzimidazoles as angiotensin ii antagonists |
| IE64514B1 (en) | 1989-05-23 | 1995-08-09 | Zeneca Ltd | Azaindenes |
| GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
| US5223499A (en) | 1989-05-30 | 1993-06-29 | Merck & Co., Inc. | 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists |
| US5332744A (en) | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
| IL94390A (en) | 1989-05-30 | 1996-03-31 | Merck & Co Inc | The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them |
| US5411980A (en) | 1989-07-28 | 1995-05-02 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists |
| EP0415886A3 (en) | 1989-08-30 | 1991-10-23 | Ciba-Geigy Ag | Aza compounds |
| US5140037A (en) | 1990-03-20 | 1992-08-18 | E. I. Du Pont De Nemours And Company | Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
| EP0533840B1 (en) | 1990-06-22 | 1996-12-11 | E.I. Du Pont De Nemours And Company | Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists |
| CA2062558A1 (en) * | 1991-03-08 | 1992-09-09 | Prasun K. Chakravarty | Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists |
| US5177074A (en) * | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| DE4110019C2 (de) | 1991-03-27 | 2000-04-13 | Merck Patent Gmbh | Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
| US5798364A (en) | 1992-03-26 | 1998-08-25 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Imidazopyridines |
| TW274551B (enExample) | 1991-04-16 | 1996-04-21 | Takeda Pharm Industry Co Ltd | |
| US5198438A (en) | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| EP0586513A1 (en) | 1991-05-10 | 1994-03-16 | Merck & Co. Inc. | Acidic aralkyl triazole derivatives active as angiotensin ii antagonists |
| IL102365A0 (en) | 1991-07-03 | 1993-01-14 | Merck & Co Inc | Substituted triazolinones,their preparation and pharmaceutical compositions containing them |
| AU2338992A (en) | 1991-07-26 | 1993-03-02 | G.D. Searle & Co. | Carbonate-substituted imidazo(4,5-d) pyridazine compounds for treatment of cardiovascular disorders |
| CZ36294A3 (en) | 1991-08-19 | 1994-07-13 | Du Pont | Substituted imidazilonone derivatives and pharmaceutical preparations based thereon |
| JPH06510763A (ja) | 1991-08-19 | 1994-12-01 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | アンジオテンシン２受容体遮断イミダゾリノン誘導体 |
| ATE146474T1 (de) | 1991-09-10 | 1997-01-15 | Tanabe Seiyaku Co | Imidazoindolizinderivate mit angiotensin-ii hemmwirkung |
| CA2077419C (en) | 1991-09-10 | 1998-08-25 | Yasushi Honma | Imidazopyridine derivatives and process for preparation thereof |
| WO1993019067A1 (en) | 1991-09-12 | 1993-09-30 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine derivatives as angiotensin ii antagonists |
| US5256667A (en) | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| GB2263637A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists |
| AU673183B2 (en) | 1992-07-10 | 1996-10-31 | Boots Company Plc, The | Dioxcyclobutene derivatives as angiotensin II antagonists |
| CA2139779A1 (en) | 1992-07-17 | 1994-02-03 | Ralph A. Rivero | Substituted biphenylmethylimidazopyridines |
| GB2272899A (en) | 1992-11-30 | 1994-06-01 | Du Pont Merck Pharma | Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles |
| JPH06312926A (ja) | 1993-03-04 | 1994-11-08 | Tanabe Seiyaku Co Ltd | アンジオテンシンｉｉ拮抗薬 |
| DE4320432A1 (de) | 1993-06-21 | 1994-12-22 | Bayer Ag | Substituierte Mono- und Bipyridylmethylderivate |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| US5424432A (en) | 1994-05-26 | 1995-06-13 | Merck & Co., Inc. | Process for the preparation of imidazolutidine |
| WO1996040256A1 (en) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone |
| IL122246A (en) | 1995-06-07 | 2004-06-01 | Searle & Co | Combination of spironolactone and angiotensin II antagonist for the treatment of heart failure |
| KR100618466B1 (ko) | 1995-06-07 | 2006-12-13 | 지.디. 썰 엘엘씨 | 울혈성심마비의치료를위한에폭시-스테로이드계알도스테론길항제및앤지오탠신ii길항제복합요법 |
| ATE314097T1 (de) | 1996-10-28 | 2006-01-15 | Amersham Health As | Kontrastmittel |
| EE9900278A (et) | 1997-01-10 | 2000-02-15 | Merck & Co., Inc. | Angiotensiin II antagonistid kasutamiseks sümptomaatilise südamepuudulikkuse ravis |
| JP2002504498A (ja) | 1998-02-25 | 2002-02-12 | メルク エンド カムパニー インコーポレーテッド | アンギオテンシンｉｉ受容体拮抗薬を用いてｑｔ分散を低下させる、または、ｑｔ分散の進行を阻害する方法 |
| GB2337701A (en) | 1998-05-26 | 1999-12-01 | United Medical And Dental Schools Of Guys St Thomas Hospitals | Treatment of ischemia with an angiotensin II antagonist |
| DE19920815A1 (de) | 1999-05-05 | 2000-11-09 | Aventis Pharma Gmbh | 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| YU78601A (sh) | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| GB0014861D0 (en) | 2000-06-16 | 2000-08-09 | Pharmacia & Upjohn Spa | Novel telomerase inhibitors |
| DE10112041A1 (de) | 2001-03-14 | 2002-09-26 | Aventis Pharma Gmbh | p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| AU2002257970B2 (en) | 2001-05-31 | 2007-08-02 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin II agonists |
| JP2003034684A (ja) | 2001-06-29 | 2003-02-07 | Biofor Inc | 新規な種類の抗真菌剤 |
| WO2003064414A1 (en) | 2002-01-29 | 2003-08-07 | Vicore Pharma Ab. | Tricyclic compounds useful as angiotensin ii agonists |
| WO2004046137A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US20060211866A1 (en) | 2005-03-21 | 2006-09-21 | Glenmark Pharmaceuticals Limited | Process for the preparation of angiotensin receptor blockers and intermediates thereof |
| US20110046090A1 (en) | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
| US20110269717A1 (en) | 2006-07-17 | 2011-11-03 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| AU2007293653B2 (en) | 2006-09-08 | 2011-02-17 | Novartis Ag | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| JP5647146B2 (ja) | 2008-12-29 | 2014-12-24 | トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． | β−アレスチンエフェクターおよび組成物およびその使用方法 |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| CN102816126A (zh) | 2011-06-07 | 2012-12-12 | 中国药科大学 | 具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途 |
| DE102012004589A1 (de) | 2012-03-09 | 2013-09-12 | Forschungszentrum Jülich GmbH | Agonisten des Angiotensin II AT2-Rezeptors zur Behandlung neurodegenerativer Erkrankungen |
| CN104583185A (zh) | 2012-08-31 | 2015-04-29 | 株式会社Api | 联芳基化合物的制造方法 |
| US9943509B2 (en) | 2013-03-15 | 2018-04-17 | University Of Southern California | Methods, compounds, and compositions for the treatment of musculoskeletal diseases |
| EP3935944A1 (en) | 2013-03-15 | 2022-01-12 | University Of Southern California, USC Stevens | Compounds for the treatment of musculoskeletal diseases |
| EP2832357A1 (en) | 2013-07-29 | 2015-02-04 | Charité - Universitätsmedizin Berlin | Selective AT2 receptor agonists for use in treatment of cachexia |
-
2017
- 2017-06-28 AR ARP170101789A patent/AR108906A1/es unknown
- 2017-06-28 BR BR112018077075-2A patent/BR112018077075A2/pt not_active Application Discontinuation
- 2017-06-28 MX MX2018015247A patent/MX2018015247A/es unknown
- 2017-06-28 ES ES17737187T patent/ES2984389T3/es active Active
- 2017-06-28 CA CA3029630A patent/CA3029630A1/en active Pending
- 2017-06-28 SG SG11201810837QA patent/SG11201810837QA/en unknown
- 2017-06-28 KR KR1020197002349A patent/KR102538999B1/ko active Active
- 2017-06-28 CN CN201780041083.0A patent/CN109715615A/zh active Pending
- 2017-06-28 WO PCT/US2017/039646 patent/WO2018005591A1/en not_active Ceased
- 2017-06-28 EP EP17737187.9A patent/EP3478672B1/en active Active
- 2017-06-28 AU AU2017289974A patent/AU2017289974B2/en not_active Ceased
- 2017-06-28 US US16/311,835 patent/US11407733B2/en active Active
- 2017-06-28 JP JP2018568791A patent/JP7231414B2/ja active Active
- 2017-06-28 TW TW106121669A patent/TW201811759A/zh unknown
- 2017-06-28 EA EA201990159A patent/EA039493B1/ru unknown
-
2018
- 2018-12-04 IL IL263499A patent/IL263499B/en unknown
-
2022
- 2022-07-11 US US17/861,809 patent/US12037324B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519586A5 (enExample) | ||
| JP2020507582A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| RU2430923C2 (ru) | Тиазолилдигидрохиназолины | |
| ME02373B (me) | Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze | |
| ES2552684T3 (es) | Nuevos compuestos de imidazolidina como moduladores del receptor de andrógenos | |
| HRP20160725T1 (hr) | Biciklični heterociklični derivati kao inhibitori fgfr kinaze za primjenu u terapiji | |
| JP2012525431A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2016520618A5 (enExample) | ||
| HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
| RU2009115963A (ru) | Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами | |
| JP2012525332A5 (enExample) | ||
| JP2014516074A5 (enExample) | ||
| RU2013151803A (ru) | Бициклические гетероциклические соединения и их применения в терапии | |
| JP2009530424A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| JP2017507122A5 (enExample) | ||
| RU2014153920A (ru) | Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний | |
| JP2019507114A5 (enExample) | ||
| JP2019512535A5 (enExample) | ||
| RU2009117705A (ru) | Производные 2-аминокарбонилпиридина | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2011526917A5 (enExample) | ||
| RU2008123388A (ru) | Соединения и композиции в качестве модуляторов lxr |